Left Ventricular Mass Progression despite Stable Blood Pressure and Kidney Function in Stage 3 Chronic Kidney DiseaseSeifert M.E.a,b,e · de las Fuentes L.c, f · Ginsberg C.f · Rothstein M.d, f · Dietzen D.J.e · Cheng S.C.d, f · Ross W.d, f · Windus D.d, f · Dávila-Román V.G.c, f · Hruska K.A.b, e
aDivision of Pediatric Nephrology, Southern Illinois University, Springfield, Ill., bDivision of Pediatric Nephrology, cCardiovascular Imaging and Clinical Research Core Laboratory, Cardiovascular Division, dRenal Division, and Departments of ePediatrics and fMedicine, Washington University, St. Louis, Mo., USA Corresponding Author
Keith A. Hruska, MD
Division of Pediatric Nephrology, Department of Pediatrics, Washington University
660 S. Euclid Ave., Campus Box 8208
St. Louis, MO 63110 (USA)
Background/Aims: Progressive chronic kidney disease (CKD) is associated with worsening cardiovascular (CV) risk not explained by traditional risk factors. Left ventricular (LV) hypertrophy (LVH) is an important CV risk factor, but its progression has not been documented in early CKD. We explored whether progression of LVH in early CKD would occur despite stable kidney function. Methods: We conducted a post hoc analysis of a 12-month study of lanthanum carbonate in stage 3 CKD, which included longitudinal assessments of CV biomarkers. Primary outcome for the analysis was the change in LV mass (LVM) indexed to height in meters2.7 (LVM/Ht2.7). Secondary outcomes were changes in blood pressure (BP), pulse-wave velocity, LV systolic/diastolic function, fibroblast growth factor 23 (FGF23), klotho, and estimated glomerular filtration rate (eGFR). Results: Thirty-one of 38 original subjects had sufficient data for analysis. LVM/Ht2.7 increased (47 ± 13 vs. 53 ± 13 g/m2.7, p = 0.006) over 12 months despite stable BP, stable eGFR and normal LV systolic function. Vascular stiffness and LV diastolic dysfunction persisted throughout the study. Klotho levels decreased (748 ± 289 to 536 ± 410 pg/ml, p = 0.03) but were unrelated to changes in LVM/Ht2.7. The change in FGF23/klotho ratio was strongly correlated with changes in LVM/Ht2.7 (r2 = 0.582, p = 0.03). Conclusion: Subjects with stage 3 CKD exhibited increasing LVM, persistent LV diastolic dysfunction and vascular stiffness despite stable kidney function, BP and LV systolic function. Abnormal FGF23 signaling due to reduced klotho expression may be associated with increasing LVM. These findings deserve further evaluation in a larger population given the adverse prognostic value of these CV biomarkers.
© 2014 S. Karger AG, Basel
Chronic kidney disease (CKD) is associated with increased cardiovascular (CV) risk compared with the general population [1,2,3]. Traditional CV risk factors such as age, sex, smoking, hypertension, cholesterol, and diabetes do not account for the increased risk in the CKD population . CV risk consists of fatal and nonfatal myocardial infarction, congestive heart failure, arrhythmias and sudden death. Biomarkers associated with CV risk include left ventricular (LV) mass (LVM), carotid-femoral pulse-wave velocity (PWV), LV systolic and LV diastolic function, and vascular calcification. Circulating biomarkers are also abnormal in CKD, worsen with progressive CKD, and illustrate an inverse correlation between glomerular filtration rate (GFR) and CV risk .
Although an estimated 10% of the general population has stage 3 CKD with an estimated GFR (eGFR) between 30 and 59 ml/min/1.73 m2, most of these individuals do not progress to end-stage kidney disease (ESKD). Moreover, patients that do progress to ESKD may do so with a variable rate of decline over a period of several months or years. Conceivably, many patients will maintain stable eGFR and remain at the same stage of CKD for years. Despite the apparent stability of kidney function, there is ongoing exposure to the pathophysiology of mild to moderate CKD, such as release of substances from the diseased kidney, hypertension, hyperphosphatemia, and vasoactive and hypertrophic signaling from the renin-angiotensin-aldosterone axis. While there are numerous longitudinal studies examining progression of biomarkers of CV risk in stage 5 CKD [6,7,8,9,10,11], there are few longitudinal studies in patients with stable mild to moderate CKD. Studies in mild to moderate CKD often use progression of CKD as an outcome measure, rather than examine those with stable CKD in a longitudinal fashion to determine changes in biomarkers associated with CV risk [12,13,14,15,16].
Recently, we published a randomized, double-blind, placebo-controlled pilot and feasibility study of the phosphorus binder lanthanum carbonate (LaCO3) in 38 patients with stage 3 CKD . Phosphorus binder therapy did not significantly affect phosphate homeostasis or biomarkers of CV risk after 12 months, but we noted a similar trend for increased LVM/Ht2.7 within the LaCO3 and placebo groups that did not reach statistical significance. Since the cohort was not significantly affected by the intervention compared to placebo, we combined the two groups for a longitudinal post hoc analysis of LVM/Ht2.7 in stable stage 3 CKD.
The original study protocol and post hoc analysis were both approved by the Human Research Protection Office at Washington University in St. Louis. Inclusion criteria, exclusion criteria and methods for stratification and randomization were published previously. Specifically relevant to the post hoc analysis, a history of prior or current congestive heart failure and severe hypertension were each exclusion criteria in the original study . Briefly, 38 subjects with stage 3 CKD were stratified for age, gender, race and diabetes status, and then randomized into 2 groups allocated 1:1 to receive either LaCO3 or a matching placebo with meals 3 times daily for 12 months. The primary end point of the original study was the change in serum phosphorus. Secondary end points included the change in mean carotid-femoral PWV, 24-hour urine phosphorus, tubular reabsorption of phosphorus, vascular calcification score, carotid artery intima-media thickness, LVM/Ht2.7, LV ejection fraction (LVEF), plasma fibroblast growth factor 23 (FGF23), plasma Dickkopf-related protein 1 (DKK1) and plasma sclerostin. LaCO3 and placebo groups were analyzed as a single cohort in this post hoc analysis since no differences in outcomes were detected during the original study.
CV assessments were performed at baseline and 12 months. PWV was determined by use of applanation tonometry of the carotid and femoral arteries (SphygmoCor, AtCor Medical, Australia) as previously described and validated [17,18,19,20,21,22]. The applanation tonometry measurements were performed by a research technician who was blinded to clinical data, echocardiographic results and treatment group. Vascular stiffness was defined as a mean PWV greater than the 50th percentile for age (9.8 m/s) using data from The Reference Values for Arterial Stiffness' Collaboration .
Two-dimensional (2D) and M-mode echocardiograms were performed as described previously . LVEF was determined by 2D echocardiography using the modified Simpson's method of disks; LVM was measured by the 2D-guided M-mode-derived cubed method and indexed to both body surface area (LVM/BSA) and height in meters raised to the power of 2.7 (LVM/Ht2.7) . Although LVM/BSA is commonly used in clinical trials, it underestimates the degree of LV hypertrophy (LVH) in overweight and obese individuals. LVM/Ht2.7 enhances the ability to detect LVH in this setting [24,25,26]. Subjects were considered to have LVH if the LVM/Ht2.7 was >51 g/m2.7. Diastolic function metrics were obtained using pulsed-wave Doppler and included early peak mitral inflow velocity (E), late peak mitral inflow velocity (A), the E/A ratio, and left atrial volume (LAV) [24,27]. Additional diastolic function metrics were obtained using pulsed-wave tissue Doppler imaging and included early diastolic lateral annular velocity (lateral e′) and the ratio of E to lateral e′ (lateral E/e′ ratio), which provides an estimate of left atrial pressure (LAP) . Normal reference values for these metrics are as follows: LAV <34 ml/m2, lateral e′ ≥10 cm/s, lateral E/e′ ratio ≤8 (also normal between 9-12 if normal LAV), E/A ratio 1-2 (along with normal LAV and normal lateral e′) [24,27]. Subjects were considered to have diastolic dysfunction if either of the following patterns were detected by echocardiography: (1) impaired myocardial relaxation: E/A <0.8, lateral e′ <10 cm/s, lateral E/e′ <8, LAV >34 ml/m2, and/or (2) increased LAP: lateral E/e′ >12 with LAV >34 ml/m2. The classification scheme for diastolic dysfunction was drawn from a recently published guideline by the American Society of Echocardiography . All measurements were performed in accordance to published guidelines and represent the average of three consecutive cardiac cycles obtained by a single observer blinded to all clinical parameters and treatment group.
Blood samples were obtained from each subject at the baseline visit and after 12 months of treatment. Plasma levels of FGF23 were measured in duplicate using a commercially available ELISA kit as previously described . Soluble klotho levels were measured in duplicate using a commercially available ELISA kit according to the manufacturer's instructions (Immuno-Biological Laboratories, Japan).
The primary outcome was the change in LVM/Ht2.7 (g/m2.7) from baseline to month 12. Secondary outcomes included changes in the nonindexed LVM (g) and LVM indexed to BSA [LVM/BSA (g/m2)], systolic blood pressure (SBP), diastolic blood pressure (DBP), carotid-femoral PWV, LVEF, E velocity, A velocity, E/A ratio, lateral e′ velocity, lateral E/e′ ratio, plasma FGF23, plasma soluble klotho, FGF23/klotho ratio and eGFR (calculated using the Modification of Diet in Renal Disease Study Equation)  from baseline to month 12.
Statistical analysis was performed by a statistician who remained blinded to the identity of the subjects and their original study groups (J.M.). The data were analyzed using the software package SAS 9.1 (Cary, N.C., USA). All outcomes were analyzed in both original treatment arms combined since there were no significant differences between groups in the original study . The distribution of each outcome variable was evaluated for normality using Kolmogorov-Smirnov Z test. Signed-rank test (non-normally distributed data) and paired t test (normally distributed data) were used to test differences of continuous variables from baseline to the 12-month visit. Bivariate correlations involving normally distributed variables were performed using Pearson's correlation. Independent categorical variables were compared using the χ2 test; paired categorical variables were compared using McNemar's test. Normally distributed data are presented as mean ± standard deviation. Non-normally distributed data are presented as median (range). All tests were two tailed; statistical significance was considered at p < 0.05.
Of the 38 subjects from the original cohort, 31 had complete demographic, biochemical, and CV data at the baseline and 12-month visit and were included in the post hoc analysis. Subjects were excluded from the analysis due to either inadequate plasma remaining for measuring circulating klotho levels or incomplete data for assessment of diastolic function, which were both outcomes not analyzed in the original study. There were no significant differences in baseline demographic or clinical data in included versus excluded subjects (data not shown). The demographic data for the combined cohort are presented in table 1. At baseline, LVH was present in 10/31 (32%) and diastolic dysfunction was present in 15/31 (48%, all with impaired myocardial relaxation: 13 had normal LAP and 2 had increased LAP; table 2).
Mean LVM/Ht2.7 significantly increased from 47.4 ± 13.2 g/m2.7 at baseline to 53.4 ± 12.9 g/m2.7 at 12 months (p = 0.006; table 2, fig. 1). The proportion of subjects with LVH increased from 32% at baseline to 48% at 12 months, but this change was not statistically significant (table 2). Of the subjects without LVH at baseline, 29% developed LVH at 12 months; in contrast, only one subject with LVH at baseline demonstrated normal LVM/Ht2.7 at 12 months. The change in LVM/Ht2.7 from baseline to the 12-month visit was similar within the original study groups (LaCO3: 45.6 ± 13.4 to 53.2 ± 13.3 g/m2.7, p = 0.44; placebo: 49.3 ± 13.2 to 53.6 ± 13.0 g/m2.7, p = 0.51). The between-group comparison of the change in LVM/Ht2.7 was not statistically significant (p = 0.36). Mean eGFR was 46 ml/min/1.73 m2 at baseline and did not significantly change during the study, demonstrating stability of stage 3 CKD during the follow-up period (table 2).
Mean nonindexed LVM significantly increased from 203 ± 79 g at baseline to 223 ± 70 g at 12 months (p = 0.02; table 2). Mean LVM/BSA also significantly increased from 100 ± 29 g/m2 at baseline to 106 ± 27 g/m2 at 12 months (p = 0.03; table 2). SBP remained stable during the study, but a small yet statistically significant decrease in DBP occurred over 12 months (table 2). We observed increased PWV, reflecting vascular stiffness at the baseline visit and at 12 months (table 2), with mean PWV greater than the 50th percentile for age (9.8 m/s) using data from The Reference Values for Arterial Stiffness' Collaboration . LVEF remained normal at >60% throughout the study, with a small but statistically significant increase from baseline to the 12-month visit (table 2).
Diastolic dysfunction was present at baseline and persisted over 12 months in many subjects, although there were no significant changes during the study (table 2). Specifically, the E velocity (median: 0.57-0.58 cm/s), A velocity (median: 0.69-0.71 cm/s), E/A ratio (median: 0.78-0.80), lateral e′ (median: 8-10 cm/s), lateral E/e′ ratio (median: 6.2-6.3), and LAV (median: 51-53 ml/m2) remained unchanged, all consistent with mild diastolic dysfunction  (table 2).
Plasma FGF23 levels were variable at the baseline visit and did not change significantly during the study (table 2). Furthermore, the change in FGF23 was not associated with the change in LVM/Ht2.7 over 12 months (Pearson's r2 = -0.02, p = 0.92; fig. 2). Mean circulating klotho levels were significantly lower at 12 months versus baseline (536 ± 410 vs. 748 ± 289 pg/ml, respectively, p = 0.03; table 2) and overall were 20-50% lower than in previous reports using the same ELISA in patients with stage 3 CKD . There was no correlation between change in soluble klotho levels and change in eGFR or LVM/Ht2.7 over 12 months (data not shown). FGF23 and klotho levels were not correlated with one another at baseline (Pearson's r2 = -0.124, p = 0.67) but were strongly correlated at 12 months (Pearson's r2 = 0.553, p = 0.04). The FGF23/klotho ratio increased significantly over 12 months (0.09 ± 0.07 to 0.26 ± 0.25, p = 0.01; table 2). Of the secondary outcomes, only the change in FGF23/klotho ratio was significantly associated with the change in LVM/Ht2.7 over 12 months (Pearson's r2 = 0.582, p = 0.03; fig. 3).
In this post hoc analysis, we identified a significant increase in LVM/Ht2.7 over a 12-month follow-up period in 31 adults with stage 3 CKD, despite stable BP, stable kidney function and normal LV systolic function. This increase remained significant across other definitions of LVM, including nonindexed LVM (g) and LVM indexed to BSA (g/m2). Given that approximately 10% of the general population has stage 3 CKD, there is a pressing need to identify biomarkers associated with poor CV outcomes. While it has been previously shown that biomarkers of CV risk (such as LVM) progressively worsen in patients with stage 5 CKD on dialysis, to our knowledge this is the first study to demonstrate progression of LVM (a biomarker that portends adverse CV risk) in an otherwise stable stage 3 CKD population.
We compared our findings with those of a recent study published by Chue et al.  that followed 109 subjects with stage 3 CKD in a 40-week placebo-controlled study using sevelamer carbonate. In their study, LVM (nonindexed and indexed to BSA) did not significantly increase in the sevelamer or placebo group over 40 weeks. An important difference between our study and that of Chue et al.  is their use of cardiac MRI rather than echocardiography to measure LVM, which precludes a direct comparison of primary outcomes between our two studies. Our two cohorts were similar in age, gender and eGFR, although our cohort had more vascular stiffness, more diastolic dysfunction, and a slightly longer follow-up period (52 vs. 40 weeks). Importantly, our cohort had lower baseline levels of circulating klotho that declined significantly over 12 months, versus higher baseline klotho levels that remained stable in Chue et al.  (using an identical ELISA kit). The decline in klotho levels in our cohort may reflect a decrease in true GFR and subclinical progression of CKD during the study that was not detected using the Modification of Diet in Renal Disease-derived eGFR, as suggested by recent studies of klotho levels as a highly sensitive biomarker of kidney injury in early CKD [30,31,32,33].
Although we detected a significant increase in LVM, this was not associated with changes in other biomarkers that have been associated with worsening CV risk such as SBP, DBP, LV systolic function, LV diastolic function, or PWV. However, it is feasible that persistently elevated PWV, a biomarker of vascular stiffness, contributed to cardiac remodeling and increasing LVM as was seen in the Multiethnic Study of Atherosclerosis . Moreover, we observed persistent, mild diastolic dysfunction over 12 months in stage 3 CKD, which has been previously reported as a correlate of increasing LVM and a strong predictor of mortality in stage 4-5 CKD [35,36].
To our surprise and in contrast to recent animal and human studies, we did not find an association between plasma FGF23 levels and the change in LVM/Ht2.7 [37,38]. However, we demonstrated a significant decline in circulating klotho levels over 12 months that was not associated with a change in LVM/Ht2.7. We suspect that the decline in circulating klotho levels reflects a loss of membrane-bound klotho from kidney tubules, as was demonstrated in a recent study by Sakan et al.  in patients with CKD. The loss of membrane-bound klotho should impair canonical FGF23 signaling in the kidney and CV system since klotho is the required coreceptor for FGF23/FGF receptor (FGFR) interactions [40,41]. However, FGF23/FGFR signaling has been demonstrated in the kidney and CV system of klotho-deficient mice [30,37]. In a seminal paper by Faul et al. , FGF23/FGFR signaling stimulated LVH in a dose-responsive pattern in klotho-haploinsufficient and klotho-knockout mouse models of CKD. However, in these animal models, lower expression of klotho was accompanied by higher plasma levels of FGF23, which were not seen in our cohort. In Faul et al. , klotho-independent FGF23/FGFR signaling was shown to induce a hypertrophic phenotype in isolated cardiac myocytes but was not tested in other resident cells playing an important role in LVH such as fibroblasts or myofibroblasts. The mechanism of klotho-independent FGF23/FGFR signaling in CKD is unknown, but one potential explanation is the promiscuous binding of FGF23 to FGFR in cardiac myocytes that is further enhanced by reduced klotho expression in the kidney and parathyroid glands . A similar paradigm has been proposed by Hu et al. , where a loss of renal klotho and an accompanying decrease in soluble klotho levels stimulated vascular calcification in animal models of CKD. Although highly speculative, our observation that the plasma FGF23/klotho ratio increased significantly over 12 months and was associated with the change in LVM/Ht2.7 could reflect a similar state of klotho-independent FGF23/FGFR signaling at the level of the myocardium in stage 3 CKD. As in the animal models of CKD in Faul et al. , this may have contributed to progression of LVM by activating hypertrophic gene programs in cardiac myocytes.
This study has several limitations inherent to post hoc analyses, the most important of which is the small sample size that limits our ability to draw inferences about the primary outcome. We computed our achieved power for detecting a difference in LVM g/m2.7 from baseline to 12 months. Using the observed mean difference of 6 g/m2.7 and standard deviation of 13 g/m2.7 at each time point, the achieved power in our post hoc analysis was 77% with a two-tailed alpha of 0.05. Thus, despite the small size of our cohort, we had modest power to detect the observed small but significant change in LVM g/m2.7. Another limitation is the lack of available plasma samples to generate data in other biomarkers of progression of LVM and heart failure in patients with CKD, such as galectin-3, ST-2, troponin I, and BNP . Exhaustion of the original samples precluded several subjects from inclusion in the post hoc analysis. These biomarkers should be included in future prospective studies of the progression of LVM in CKD.
In conclusion, subjects with CKD stage 3 exhibited a progressive increase in LVM with persistent LV diastolic dysfunction and vascular stiffness over 12 months despite stable kidney function, BP and normal LV systolic function. The change in FGF23/klotho ratio was associated with increasing LVM, which may reflect klotho-independent FGF23 signaling in cardiac myocytes that has been associated with LVH in animal models of CKD. These findings deserve further evaluation in a larger population given the adverse prognostic value of progression of these CV biomarkers.
The authors are grateful to Jingnan Mao for her assistance as a statistician. The LaCO3 and matched placebo in the original study were provided by Shire US Pharmaceuticals Inc. The study was funded by Shire US Pharmaceuticals Inc., and by NIH grants DK 070790 (K.A.H.), KL2 RR024994 and UL1 RR024992 (M.E.S. and Washington University), and L40 DK099748-01 (M.E.S.).
K.A.H. has been a consultant for or the recipient of research funding from Shire, Genzyme and Fresenius.
Keith A. Hruska, MD
Division of Pediatric Nephrology, Department of Pediatrics, Washington University
660 S. Euclid Ave., Campus Box 8208
St. Louis, MO 63110 (USA)
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.